{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:47:52Z","timestamp":1788569272198,"version":"build-2803163510"},"reference-count":59,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1532,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1111\/j.1600-0609.2011.01618.x","type":"journal-article","created":{"date-parts":[[2011,3,29]],"date-time":"2011-03-29T15:21:59Z","timestamp":1301412119000},"page":"54-60","source":"Crossref","is-referenced-by-count":56,"title":["Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis"],"prefix":"10.1111","volume":"87","author":[{"given":"Vibe","family":"Skov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Stauffer","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Hasselbalch","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten K.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Weis","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben A.","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Carl","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,6,22]]},"reference":[{"issue":"Suppl 2","key":"10.1111\/j.1600-0609.2011.01618.x-BIB1|cit1","first-page":"3","article-title":"The chronic myeloproliferative disorders","volume":"36","author":"Tefferi","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"Mechanisms of disease. The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2007-11-121434","article-title":"A dynamic prognostic model to predict survival in postpolycythemia vera myelofibrosis","volume":"111","author":"Passamonti","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocytosis, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"TET2 mutations in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Finazzi","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.beha.2005.07.007","article-title":"Evidence-based management of polycythemia vera","volume":"19","author":"Barbui","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1182\/blood-2006-12-038968","article-title":"How I treat polycythemia vera","volume":"109","author":"Finazzi","year":"2007","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1111\/j.1600-0609.2011.01618.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/10428199609074371","article-title":"Interferon-alpha in the treatment of essential thrombocythemia","volume":"22","author":"Lengfelder","year":"1996","journal-title":"Leukemia Lymphoma"},{"issue":"Suppl 1","key":"10.1111\/j.1600-0609.2011.01618.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/10428199609074372","article-title":"Interferon treatment in polycythaemia vera","volume":"22","author":"Reilly","year":"1996","journal-title":"Leukemia Lymphoma"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s002770050554","article-title":"The role of interferon alpha in the treatment of idiopathic myelofibrosis","volume":"78","author":"Bachleitner-Hofmann","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1055\/s-2006-942761","article-title":"Pegylated interferon therapy or patients with Philadelphia chromosome negative myeloproliferative disorders","volume":"32","author":"Quintas-Cardama","year":"2006","journal-title":"Sem Thromb Hemostas"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.22026","article-title":"Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha","volume":"107","author":"Silver","year":"2006","journal-title":"Cancer"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/cncr.21900","article-title":"A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia. Feasibility, clinical and biologic effects, and impact on quality of life","volume":"106","author":"Samuelsson","year":"2006","journal-title":"Cancer"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.23018","article-title":"PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders. Final results of a phase 2 study","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms","volume":"22","author":"Kiladjian","year":"2008","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon-alfa-2a therapy yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1179\/102453309X12473408860587","article-title":"Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete haematological remission","volume":"14","author":"Larsen","year":"2009","journal-title":"Hematology"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB28|cit28","first-page":"3940","article-title":"Gene expression profiling in polycythemia vera using cDNA microarray technology","volume":"63","author":"Pellagatti","year":"2003","journal-title":"Cancer Res"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2141.2005.05416.x","article-title":"Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2","volume":"129","author":"Goerttler","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/stemcells.2004-0131","article-title":"Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays","volume":"23","author":"Jones","year":"2005","journal-title":"Stem Cells"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood-2005-05-1889","article-title":"Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2","volume":"106","author":"Kralovics","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1634\/stemcells.2006-0351","article-title":"Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms\u2019 tumor gene 1 (WT1)","volume":"25","author":"Guglielmelli","year":"2007","journal-title":"Stem Cells"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/leu.2008.112","article-title":"Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia","volume":"22","author":"Puigdecanet","year":"2008","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2008.357","article-title":"Molecular profile of CD34+ stem\/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia","volume":"23","author":"Catani","year":"2009","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1479-5876-7-39","article-title":"Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a","volume":"7","author":"Slezak","year":"2009","journal-title":"J Transl Med"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/1078-0432.CCR-10-1092","article-title":"Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F","volume":"16","author":"Berkofsky-Fessler","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","article-title":"Exploration, normalization, and summaries of high density oligonucleotide array probe level data","volume":"4","author":"Irizarry","year":"2003","journal-title":"Biostatistics"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2307\/1390807","article-title":"R: a language for data analysis and graphics","volume":"5","author":"Ihaka","year":"1996","journal-title":"J Comput Graph Stat"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and empirical bayes methods for assessing differential expression in microarray experiments","volume":"3","author":"Smyth","year":"2004","journal-title":"Stat Appl Genet Mol Biol"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"JR Statist Soc B"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB41|cit41","first-page":"4096","article-title":"Identification of a new interferon a-inducible gene (p27) on human chromosome 14q32 and its expression in breast carcinoma","volume":"53","author":"Rasmussen","year":"1993","journal-title":"Cancer Res"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1006\/cyto.1999.0549","article-title":"The interferon-induced gene ISG12 is regulated by various cytokines as the gene 6-16 in human cell lines","volume":"12","author":"Gjermandsen","year":"2000","journal-title":"Cytokine"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.0022-202X.2004.22322.x","article-title":"Interferon alpha-inducible protein 27 (IFI27) is upregulated in psoriatric skin and certain epithelial cancers","volume":"122","author":"Suomela","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1038\/sj.jid.5700884","article-title":"Human basal cell carcinoma is associated with Foxp3 T cells in a Th2 dominant microenvironment","volume":"127","author":"Kaporis","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB45|cit45","first-page":"12","article-title":"Confirmation of differentially expressed genes in normal and tumor tissues using clontech cancer profiling assays","volume":"XVIII","author":"Mengwasser","year":"2003","journal-title":"Clontechniques"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(03)13308-9","article-title":"Gene expression predictors of breast cancer outcomes","volume":"361","author":"Huang","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1349-7006.2004.tb02189.x","article-title":"Distinct pattern of gene expression in pyothorax-associtaed lymphoma (PAL), a lymphoma developing in long-standing inflammation","volume":"95","author":"Nishia","year":"2004","journal-title":"Cancer Sci"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.leukres.2008.06.002","article-title":"Myelofibrosis with myeloid metaplasia. The advanced phase of an untreated disseminated haematological cancer. Time to change our therapeutic attitude with early up-front treatment at the time of diagnosis","volume":"33","author":"Hasselbalch","year":"2009","journal-title":"Leuk Res"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ajh.2830250215","article-title":"A distinct subtype of idiopathic myelofibrosis with bone marrow features mimicking hairy cell leukemia: evidence of an autoimmune pathogenesis","volume":"25","author":"Hasselbalch","year":"1987","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00005792-199405000-00003","article-title":"Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus","volume":"73","author":"Paquette","year":"1994","journal-title":"Medicine (Baltimore)"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/08916930310001625952","article-title":"Microarray analysis of interferon-regulated genes in SLE","volume":"36","author":"Crow","year":"2003","journal-title":"Autoimmunity"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1002\/art.20798","article-title":"Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus","volume":"50","author":"Kirou","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.coi.2004.09.014","article-title":"The emerging role of interferon in human systemic lupus erythematosus","volume":"16","author":"Baechler","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/0961203310371161","article-title":"The interferon-alpha signature of systemic lupus erythematosus","volume":"19","author":"Obermoser","year":"2010","journal-title":"Lupus"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000057631","article-title":"Immune-mediated complications during interferon therapy in haematological patients","volume":"107","author":"Raanani","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1111\/j.1600-0609.2011.01618.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat Rev Immunol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2011.01618.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0609.2011.01618.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T18:53:45Z","timestamp":1741114425000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2011.01618.x"}},"subtitle":["Transcriptional profiling of IFN-inducible genes in CMPNs"],"short-title":[],"issued":{"date-parts":[[2011,6,22]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01618.x","relation":{},"ISSN":["0902-4441"],"issn-type":[{"value":"0902-4441","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6,22]]}}}